Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis

Cellular Signalling

Volumn 23, Issue 1, 2011, Pages 152-160

  Abusnina, Abdurazzag ^a   Alhosin, Mahmoud ^a   Keravis, Thérèse ^a   Muller, Christian D ^a   Fuhrmann, Guy ^a   Bronner, Christian ^a   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Acute lymphoblastic leukemia; Cyclic nucleotide phosphodiesterase; Epigenetic integrator UHRF1; Jurkat cell; PDE1; Tumor suppressor p73

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE 1A; PROTEIN P73; RING FINGER PROTEIN; THYMOQUINONE; UBIQUITIN LIKE PHD RING FINGER 1 PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CCAAT-ENHANCER-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 1; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; ISOENZYMES; JURKAT CELLS; NUCLEAR PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS;

NIGELLA SATIVA;

EID: 77957800149     PISSN: 08986568     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellsig.2010.08.015     Document Type: Article

References (55)

1. Nagi M.N., Mansour M.A. Pharmacol. Res. 2000, 41:283.
2. Salomi N.J., Nair S.C., Jayawardhanan K.K., Varghese C.D., Panikkar K.R. Cancer Lett. 1992, 63:41.
3. Worthen D.R., Ghosheh O.A., Crooks P.A. Anticancer Res. 1998, 18:1527.
4. Gali-Muhtasib H., Roessner A., Schneider-Stock R. Int. J. Biochem. Cell Biol. 2006, 38:1249.
5. Shoieb A.M., Elgayyar M., Dudrick P.S., Bell J.L., Tithof P.K. Int. J. Oncol. 2003, 22:107.
6. Gali-Muhtasib H., Diab-Assaf M., Boltze C., Al-Hmaira J., Hartig R., Roessner A., Schneider-Stock R. Int. J. Oncol. 2004, 25:857.
7. Gali-Muhtasib H.U., Abou Kheir W.G., Kheir L.A., Darwiche N., Crooks P.A. Anticancer Drugs 2004, 15:389.
8. Roepke M., Diestel A., Bajbouj K., Walluscheck D., Schonfeld P., Roessner A., Schneider-Stock R., Gali-Muhtasib H. Cancer Biol. Ther. 2007, 6:160.
9. Gali-Muhtasib H., Kuester D., Mawrin C., Bajbouj K., Diestel A., Ocker M., Habold C., Foltzer-Jourdainne C., Schoenfeld P., Peters B., Diab-Assaf M., Pommrich U., Itani W., Lippert H., Roessner A., Schneider-Stock R. Cancer Res. 2008, 68:5609.
10. Alhosin M., Abusnina A., Achour M., Sharif T., Muller C., Peluso J., Chataigneau T., Lugnier C., Schini-Kerth V.B., Bronner C., Fuhrmann G. Biochem. Pharmacol. 2010, 79:1251.
11. Bronner C., Achour M., Arima Y., Chataigneau T., Saya H., Schini-Kerth V.B. Pharmacol. Ther. 2007, 115:419.
12. Achour M., Jacq X., Ronde P., Alhosin M., Charlot C., Chataigneau T., Jeanblanc M., Macaluso M., Giordano A., Hughes A.D., Schini-Kerth V.B., Bronner C. Oncogene 2008, 27:2187.
13. Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S., Jacobsen S.E. Science 2007, 317:1760.
14. Arita K., Ariyoshi M., Tochio H., Nakamura Y., Shirakawa M. Nature 2008, 455:818.
15. Hashimoto H., Horton J.R., Zhang X., Bostick M., Jacobsen S.E., Cheng X. Nature 2008, 455:826.
16. Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., Arrowsmith C.H., Dhe-Paganon S. Nature 2008, 455:822.
17. Karambataki M., Malousi A., Maglaveras N., Kouidou S. Neuromolecular Med. 2010, 12:260-269.
18. Sharif T., Auger C., Alhosin M., Ebel C., Achour M., Etienne-Selloum N., Fuhrmann G., Bronner C., Schini-Kerth V.B. Eur. J. Cancer 2010, 46:983.
19. Sharif T, Auger C, Bronner C, Alhosin M, Klein T, Etienne-Selloum N, Schini-Kerth VB, Fuhrmann G, Invest. New Drugs, doi:10.1007/s10637-009-9352-3.
20. Beretz A., Anton R., Stoclet J.C. Experientia 1978, 34:1054.
21. Orallo F., Alvarez E., Basaran H., Lugnier C. Naunyn Schmiedebergs Arch Pharmacol. 2004, 370:452.
22. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., Huang H.L. Biochem. Pharmacol. 2004, 68:2087.
23. Lugnier C. Pharmacol. Ther. 2006, 109:366.
24. McConkey D.J., Orrenius S. Stem Cells 1996, 14:619.
25. Fraser M., Chan S.L., Chan S.S., Fiscus R.R., Tsang B.K. Oncogene 2006, 25:2203.
26. Pastan I., Johnson G.S., Anderson W.B. Annu. Rev. Biochem. 1975, 44:491.
27. Friedman D.L., Johnson R.A., Zeilig C.E. Adv. Cyclic Nucleotide Res. 1976, 7:69.
28. Jiang X., Li J., Paskind M., Epstein P.M. Proc. Natl Acad. Sci. USA 1996, 93:11236.
29. Favot L., Keravis T., Lugnier C. Thromb. Haemost. 2004, 92:634.
30. Nagel D.J., Aizawa T., Jeon K.I., Liu W., Mohan A., Wei H., Miano J.M., Florio V.A., Gao P., Korshunov V.A., Berk B.C., Yan C. Circ. Res. 2006, 98:777.
31. Marivet M.C., Bourguignon J.J., Lugnier C., Mann A., Stoclet J.C., Wermuth C.G. J. Med. Chem. 1989, 32:1450.
32. Lugnier C., Bruch M., Stoclet J.-C., Strub M.P., Marivet M., Wermuth C.G. Eur. J. Med. Chem. 1985, 20:121.
33. Coste H., Grondin P. Biochem. Pharmacol. 1995, 50:1577.
34. Hopfner R., Mousli M., Jeltsch J.M., Voulgaris A., Lutz Y., Marin C., Bellocq J.P., Oudet P., Bronner C. Cancer Res. 2000, 60:121.
35. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. J. Biol. Chem. 1951, 193:265.
36. Keravis T., Thaseldar-Roumie R., Lugnier C. Meth. Mol. Biol. 2005, 307:63.
37. Stoclet J.C., Keravis T., Komas N., Lugnier C. Exp. Opin. Investig. Drugs 1995, 4:1081.
38. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J.C. Biochem. Pharmacol. 1986, 35:1743.
39. Kameni Tcheudji J.F., Lebeau L., Virmaux N., Maftei C.G., Cote R.H., Lugnier C., Schultz P. J. Mol. Biol. 2001, 310:781.
40. Campos-Toimil M., Keravis T., Orallo F., Takeda K., Lugnier C. Br. J. Pharmacol. 2008, 154:82.
41. D'Sa C., Tolbert L.M., Conti M., Duman R.S. J. Neurochem. 2002, 81:745.
42. Abrahamsen H., Baillie G., Ngai J., Vang T., Nika K., Ruppelt A., Mustelin T., Zaccolo M., Houslay M., Taskén K. J. Immunol. 2004, 173:4847.
43. Baillie G.S., MacKenzie S.J., McPhee I., Houslay M.D. Br. J. Pharmacol. 2000, 131:811.
44. Creighton J., Zhu B., Alexeyev M., Stevens T. J. Cell Sci. 2008, 121:110.
45. Erdogan S., Houslay M.D. Biochem. J. 1997, 321:165.
46. Seybold J., Newton R., Wright L., Finney P.A., Suttorp N., Barnes P.J., Adcock I.M., Giembycz M.A. J. Biol. Chem. 1998, 173:20575.
47. Lugnier C., Follenius A., Gerard D., Stoclet J.C. Eur. J. Pharmacol. 1984, 98:157.
48. Dent G., Giembycz M.A., Rabe K.F., Barnes P.J. Br. J. Pharmacol. 1991, 103:1339.
49. Lerner A., Kim D.H., Lee R. Leuk. Lymphoma 2000, 37:39.
50. Meyers J.A., Su D.W., Lerner A. J. Immunol. 2009, 182:5400.
51. Tiwari S., Dong H., Kim E.J., Weintraub L., Epstein P.M., Lerner A. Biochem. Pharmacol. 2005, 69:473.
52. Zhang L., Murray F., Zahno A., Kanter J.R., Chou D., Suda R., Fenlon M., Rassenti L., Cottam H., Kipps T.J., Insel P.A. Proc. Natl Acad. Sci. USA 2008, 105:19532.
53. Sato J., Nair K., Hiddinga J., Eberhardt N.L., Fitzpatrick L.A., Katusic Z.S., O'Brien T. Cardiovasc. Res. 2000, 47:697.
54. Fukumoto S., Koyama H., Hosoi M., Yamakawa K., Tanaka S., Morii H., Nishizawa Y. Circ. Res. 1999, 85:985.
55. Abbady A.Q., Bronner C., Bathami K., Muller C.D., Jeanblanc M., Mathieu E., Klein J.P., Candolfi E., Mousli M. Biochem. Pharmacol. 2005, 570.